Navigation Links
Combination antibody therapy shows promise in metastatic melanoma
Date:6/3/2011

BOSTON--A duo of drugs, each targeting a prime survival strategy of tumors, can be safely administered and are potentially more effective than either drug alone for advanced, inoperable melanomas, according to a phase 1 clinical trial led by Dana-Farber Cancer Institute investigators.

The findings (abstract 8511), will be presented in an oral session at the annual meeting of the American Society of Clinical Oncology on Saturday, June 4, 3 p.m. CT, Arie Crown Theater, McCormick Place.

The drugs -- ipilimumab and bevacizumab -- are both monoclonal antibodies, intensified formulations of natural disease-fighting proteins. Ipilimumab spurs the immune system to attack diseased cells, including tumor cells. Bevacizumab, also known by the trade name Avastin, blocks the growth of blood vessels that provide tumors with nourishment. Ipilimumab has extended the lives of metastatic melanoma patients in previous clinical trials, and bevacizumab is often used to treat tumors of the colon, lung, and kidney.

The trial involved 22 patients with metatastic melanoma that was not treatable by surgery.

F. Stephen Hodi, MD, the study's lead author and director of the melanoma treatment center at Dana-Farber, said the trial is the first to explore whether the two agents enhance each other's effectiveness. Most of the participants didn't experience serious adverse side effects, although some did experience inflammation of artery walls, the liver, thyroid gland, colon, or uvea (the middle layer of the eye). Five patients required steroid treatment for these problems and were removed the trial.

Positron emission tomography (PET) scans showed a prompt immune system response to many of the melanoma tumors, and computed tomography (CT) scans showed decreased blood flow to the tumors. Eight of the participants had partial responses -- showing some tumor shrinkage -- to the dual treatment, and six had stable disease. All the responses lasted at least six months. Biopsies performed after the treatment showed a more vigorous immune system response than would be expected with ipilimumab alone.

"Our findings indicate that ipilimumab and bevacizumab can be safely administered with careful management of side effects," said Hodi. "The results of lab tests suggest that the two agents may work synergistically, with 14 of 21 evaluable patients experiencing a clinical benefit. This approach merits exploration in further clinical trials."


'/>"/>

Contact: Bill Schaller
william_schaller@dfci.harvard.edu
617-632-5357
Dana-Farber Cancer Institute
Source:Eurekalert

Related medicine news :

1. Combination therapy shows promise for rare, deadly cancer caused by asbestos
2. Less toxic combination of erlotinib and bevacizumab is effective non-small cell lung cancer patients
3. Model developed to improve combination vaccine accessibility worldwide
4. Gene combinations are found to be related to hip osteoporosis in postmenopausal women
5. Smoking in combination with immunosuppression poses greater risk for transplant-related carcinoma
6. Combination overcomes breast cancer resistance to herceptin
7. New combination therapy for solid tumors?
8. Certain Drug Combinations May Beat Back Aggressive Breast Cancer
9. Drug combination shows promise for newly diagnosed blood cancer patients, study finds
10. Combination therapy improves survival time for patients with advanced liver cancer
11. Best drug development results from computer/test tube combination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... ... performance connectors, is now promoting to the US market its advanced highly customizable ... LAMTAC® and ODU TURNTAC®. These advanced technologies are ideal for a wide ...
(Date:12/7/2016)... ... December 07, 2016 , ... One of two inventors from Glen Burnie, Md., ... painful for her. "This is why the co-inventor and I have designed a new ... then created a prototype of the patent-pending AV-AIR, a device that serves as an ...
(Date:12/7/2016)... ... ... Sharon Kleyne, host of the nationally syndicated radio program, The Sharon Kleyne ... declared on her radio program in November 2016 the need to educate people about ... leaders in corporate America, they are trying to take advantage of successful algorithms and ...
(Date:12/7/2016)... ... December 07, 2016 , ... Texas Premier Locksmith ... carried out by unethical locksmith companies and is urging Search Engines to improve ... to Texas Premier Locksmith, these fraudulent locksmith services take advantage of consumers locked ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... 2016 BOC Business Brilliance Awards under the Best New Product Launch category. Gensuite’s ... achieved through user experience. , BOC Global Events & Training Group is a ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... 7, 2016  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS ), ... a company overview at the BMO Capital Markets Prescriptions for Success ... NY . A live webcast of the presentation ... Ionis website.  The replay will be available within 48 hours and ... ...
(Date:12/7/2016)... 2016 According to the latest ... Market Study on Multiplex Detection Immunoassay: North America to ... global multiplex detection immunoassay market is expected to witness a CAGR ... ...      (Logo: http://photos.prnewswire.com/prnh/20161114/438683LOGO) ...
(Date:12/7/2016)... , December 7, 2016 ... reach a value of USD 3.9 billion by ... View Research, Inc. The growth of the market ... and continuous technological advancements by the market players. ... due to increasing donation, rising awareness about transfusion-transmitted ...
Breaking Medicine Technology: